Os 15 principais medicamentos para câncer, mais vendidos em 2022

Especialistas projetam as vendas dos 15 principais medicamentos para câncer em 2022:

1. Revlimid (lenalidomide) Celgene 2015 sales: $5.80 billion 2022 sales: $13.44 billion
2. Opdivo (nivolumab) Bristol-Myers Squibb e Ono Pharmaceutical 2015 sales: $1.12 billion 2022 sales: $12.62 billion
3. Imbruvica (ibrutinib) AbbVie (Pharmacyclics); Johnson & Johnson 2015 sales: $1.23 billion 2022 sales: $8.29 billion
4. Keytruda (pembrolizumab) Merck & Co. 2015 sales: $566 million 2022 sales: $6.56 billion
5. Ibrance (palbociclib) Pfizer 2015 sales: $723 million 2022 sales: $6.01 billion
6. Tecentriq (atezolizumab) Roche 2015 sales: N/A 2022 sales: $5.53 billion
7. Darzalex (daratumumab) Johnson & Johnson 2015 sales: $20 million 2022 sales: $4.91 billion
8. Perjeta (pertuzumab) Roche 2015 sales: $1.50 billion 2022 sales: $4.73 billion
9. Xtandi (enzalutamide) Astellas e Pfizer 2015 sales: $2.10 billion 2022 sales: $4.71 billion
10. Avastin (bevacizumab) Roche 2015 sales: $6.95 billion 2022 sales: $4.68 billion
11. Herceptin (trastuzumab) Roche 2015 sales: $6.79 billion 2022 sales: $3.98 billion
12. Gazyva (obinutuzumab) Roche 2015 sales: $133 million 2022 sales: $3.43 billion
13. Jakafi (ruxolitinib) Incyte e Novartis 2015 sales: $1.01 billion 2022 sales: $3.10 billion
14. Venclexta (venetoclax) AbbVie e Roche 2015 sales: N/A 2022 sales: $2.91 billion
15. Rituxan (rituximab) Roche e Pharmstandard - 2015 sales: $7.39 billion 2022 sales: $2.89 billion

Republicado por:RM Consult